Press release
Pioneering Solutions in the Respiratory Syncytial Virus (RSV) Therapeutics Market: Market Size, Growth Projections, and Competitive Strategies
Respiratory Syncytial Virus RSV Therapeutics Market
The Business Research Company offers in-depth market insights through Respiratory Syncytial Virus RSV Therapeutics Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.
The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
Market Segmentation:
The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented -
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Major Driver - The Rise In The Prevalence Of Rsv Infection
The rise in the prevalence of RSV infection is driving the growth of the respiratory syncytial virus (RSV) therapeutics market going forward. RSV is a prevalent respiratory illness that can result in mild to severe respiratory infections, especially in newborns, young children, elderly adults, and people with compromised immune systems. Increasing RSV infections prompt the development of innovative treatments to address the rising need and mitigate the severity of RSV-related complications. For instance, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, around 11,255 new cases of RSV were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020-21. Therefore, the rise in the prevalence of RSV infection propels the growth of the respiratory syncytial virus (RSV) therapeutics market.
Competitive Landscape:
Major companies operating in the respiratory syncytial virus (rsv) therapeutics market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report
Top Trend - Pfizer's Abrysvo Approval Marks A Significant Advancement In Respiratory Syncytial Virus (RSV) Therapeutics
Developing new drugs and vaccines with better efficacy is a key trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market. Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focused on developing new drugs and vaccines to sustain their position in the market. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, received approval from the Food and Drug Administration, a US-based federal agency responsible for protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent lower respiratory tract sickness caused by RSV in people 60 and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties, and it has been clinically proven to be safe and productive.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Respiratory Syncytial Virus RSV Therapeutics Market Characteristics
3. Respiratory Syncytial Virus RSV Therapeutics Market Trends And Strategies
4. Respiratory Syncytial Virus RSV Therapeutics Market - Macro Economic Scenario
5. Respiratory Syncytial Virus RSV Therapeutics Market Size And Growth
…..
27. Respiratory Syncytial Virus RSV Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pioneering Solutions in the Respiratory Syncytial Virus (RSV) Therapeutics Market: Market Size, Growth Projections, and Competitive Strategies here
News-ID: 3434475 • Views: …
More Releases from The Business research company
Gene Synthesis Market Flourishes: Envisions $7.09 Billion Realm by 2033, Pioneer …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Gene Synthesis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $7.09 billion In 2028 At…
Food Diagnostics Market Expands: $25.1 Billion Market by 2033, Safeguarding Food …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Food Diagnostics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $25.1 billion In 2028 At…
Fire Protection System Market Ignites: Securing $113.83 Billion Segment with Str …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Fire Protection System Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $113.83 billion In 2028…
Fashion Design And Production Software Market Innovates: $3.45 Billion Potential …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Fashion Design And Production Software Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.45 billion…
More Releases for RSV
RSV Diagnostics Market | Pin-Point Analysis for Changing Competitive Dynamics
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting…
Global RSV Diagnostics Market 2018-2025 bio Mérieux, Abbott, Roche, BD
A market study "Global RSV Diagnostics Market" examines the performance of the RSV Diagnostics market 2018. It encloses an in-depth Research of the RSV Diagnostics market state and the competitive landscape globally. This report analyzes the potential of RSV Diagnostics market in the present and the future prospects from various angles in detail.
The Global RSV Diagnostics Market 2018 report includes RSV Diagnostics market Revenue, market Share, RSV Diagnostics industry volume,…
RSV Diagnostics Market Trend | Industry Analysis Report, 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting…
RSV Diagnostics Market Set to Surge Significantly During 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting…
Global Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics Sales Market R …
Qyresearchreports include new market research report "Global Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics Sales Market Report 2017" to its huge collection of research reports.
This research report gives a definitive review on the Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics as in light of a segmented pattern. Entry variables managed in the report incorporate the distinctive services or products offered by the market players alongside the free market activity scales…
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis An …
Summary
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such…
